Tag: GLP-1
ResMed sees nothing but ‘tailwind’
April 26, 2024Liz Beaulieu, Editor
SAN DIEGO – The impact of GLP-1 drugs on the CPAP therapy market has stolen the headlines recently, but ResMed Chairman and CEO Mick Farrell says the impact of wearables might be “a higher tidal wave.”
Farrell, on a recent conference call to discuss the company’s financial results for the third quarter of its fiscal year 2024, noted the Samsung Galaxy Watch’s recent de novo authorization from the U.S. Food and Drug Administration to detect signs of sleep apnea...
CCS ‘on right track’
March 13, 2024Theresa Flaherty, Managing Editor
GLP-1 medications misconception: Nearly 60% of diabetes patients surveyed by CCS mistakenly believe that GLP-1 medications alone are a silver bullet for managing their health. However, these drugs need to be integrated into a long-term holistic care plan.
Education and support gap: The survey results highlight a real need for better education and support for patients managing their diabetes. Diabetes suppliers are well-positioned to...
CCS survey: Education lacking for diabetes
March 7, 2024HME News Staff
DALLAS – CCS engaged independent market research firm PureSpectrum to survey more than 1,500 people living with diabetes to understand their attitude on an array of timely issues, including growing demand for GLP-1 weight loss drugs.
The survey found 57% of people with diabetes think GLP-1 weight loss drugs alone may be a silver bullet for helping achieve their health goals.
“GLP-1 weight loss drugs alone are not a silver bullet when it comes to improving the health...